A. R. Dixon

Verona Pharma (United Kingdom) — United Kingdom

Medicine · Health Sciences

27h-index2.4kcitations91works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Surgical Treatments(34), Anorectal Disease Treatments and Outcomes(19), Pelvic floor disorders treatments(15), Chronic Obstructive Pulmonary Disease (COPD) Research(14), Hernia repair and management(11)

Publications91 total

ENSIFENTRINE IMPROVED LUNG FUNCTION, SYMPTOMS, QUALITY OF LIFE, AND EXACERBATION RATE AND RISK REGARDLESS OF SEX
CHEST Journal·2025
ENSIFENTRINE IMPROVED SLEEP IN PATIENTS WITH MODERATE-TO-SEVERE COPD IN THE PHASE 3 ENHANCE TRIALS
CHEST Journal·2025
The effect of ensifentrine on COPD symptoms and quality of life according to baseline dyspnea level
2025
The effect of ensifentrine on lung function and exacerbations in patients with COPD according to baseline dyspnea
2025
Lung Function and Safety Outcomes in Patients With Moderate-to-Severe COPD Treated With Ensifentrine
CHEST Pulmonary·2025Open Access
Progression from GOLD A/B to GOLD E: a claims analysis of patients with COPD newly initiating inhaled therapy
BMC Pulmonary Medicine·2025· 1 citedOpen Access
Burden of Exacerbations in Patients Newly Initiating an Inhaled Regimen for COPD: A Claims Analysis
International Journal of COPD·2025Open Access
Ensifentrine Monotherapy Improved Lung Function and Reduced Exacerbation Rate and Risk in Symptomatic Patients With Moderate-to-Severe COPD
American Journal of Respiratory and Critical Care Medicine·2025
Ensifentrine Monotherapy Reduced Dyspnea and Improved Quality of Life in Patients With Symptomatic, Moderate-to-Severe COPD
American Journal of Respiratory and Critical Care Medicine·2025
Differences in COPD management across clinician type: Maintenance treatment habits and patient characteristics among US pulmonologists, internal/family medicine physicians, nurse practitioners, and physician assistants
Chronic Respiratory Disease·2025Open Access
Patient Burden and Insights in COPD: A Survey Analysis
Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation·2025· 1 citedOpen Access
ENSIFENTRINE IMPROVED LUNG FUNCTION IN PATIENTS WITH MODERATE TO SEVERE COPD: A POOLED ANALYSIS FROM THE PHASE 3 ENHANCE TRIALS
CHEST Journal·2024
ENSIFENTRINE IMPROVED LUNG FUNCTION, SYMPTOMS, AND QUALITY OF LIFE REGARDLESS OF COPD SEVERITY
CHEST Journal·2024
Ensifentrine improved lung function and reduced moderate/severe exacerbation rate and risk in patients with COPD regardless of chronic bronchitis history
2024
Efficacy and safety of ensifentrine in European patients with moderate to severe COPD: pooled results from the ENHANCE trials
2024· 1 cited
Ensifentrine treatment improves COPD symptoms and quality of life in a pooled analysis of the ENHANCE trials
2024
Ensifentrine improved symptoms and reduced moderate/severe exacerbation rate and risk in patients with COPD and significant cough and sputum
2024· 1 cited
Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of the ENHANCE trials
Expert Review of Respiratory Medicine·2024· 11 citedOpen Access
Pacemaker-lead-associated thrombosis in dogs: a multicenter retrospective study
Journal of Veterinary Cardiology·2023· 3 citedOpen Access
Hypercoagulability in dogs with chronic enteropathy and association with serum albumin concentration
Journal of Veterinary Internal Medicine·2021· 11 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

G. L. Greenslade(13), K Gash(7), S. Slawik(4), A. Goede(4), William Chambers(3), N. Zafar(3), Kathryn McCarthy(3), B. N. Chaudhary(3), Damian G. Glancy(3), K. Mabey(3), Robert I. Nicholson(2), R A McClelland(2), R.W. Blamey(2), M. Bicsak(2), Ian Lindsey(2), Boris Vestweber(2), H. Carter(2), Angela M. Mills(2), Simon Phillips(2), Haytham Sumrien(2)